Presentation Information
[2-MO17-1]Phase I clinical trial of [211At]NaAt for refractory thyroid cancer (Alpha-T1 trial)
Watabe Tadashi1、Kosuke Mukai1、Sadahiro Naka2、Hidetaka Sasaki2、Takashi Kamiya2、Atsunori Fukuhara1、Yoshifumi Shirakami1、Kazuhiro Ooe1、Kayako Isohashi1、Iichiro Shimomura1、Noriyuki Tomiyama1 (1.The University of Osaka, Osaka, Japan、2.The University of Osaka Hospital, Osaka, Japan)